17 Feb 3rd GENERATION INS APPROVED WITH 2-PROGRAM REMOTE
A PMA supplement for the newest implantable neurostimulator (INS) was approved by the FDA. This marks the 6th FDA approval Axonics has been granted for a product innovation since November 2019. The newest INS has upgraded embedded software that improves the Key-fob remote functionality. Specifically, the modifications allow for broader stimulation parameter adjustments at home with the addition of a 2nd therapy program to select based on an algorithm from intraoperative results. This updated remote will be helpful for patients who travel a long distance or those utilizing telemedicine. I have updated my OAB Care Pathway to reflect these ongoing SNM innovations.